Location History:
- 1335 Snaroya, NO (2001)
- Snarøya, NO (2015)
- Snaroya, NO (2015 - 2022)
- Oslo, NO (2014 - 2024)
Company Filing History:
5 out of 13 
4 out of 5 
3 out of 6 
Years Active: 2001-2025
Title: Bjarne Bogen: Innovator in Vaccine Technology
Introduction
Bjarne Bogen is a prominent inventor based in Snaroya, Norway. He has made significant contributions to the field of vaccine technology, holding a total of 15 patents. His work focuses on developing innovative solutions for enhancing immune responses through advanced vaccine compositions.
Latest Patents
Bogen's latest patents include groundbreaking technologies related to vaccine molecules. One of his notable inventions involves a mixture of immunogenic vaccine molecules designed to target dimeric vaccine molecules to antigen-presenting cells. This technology aims to elicit a robust immunogenic response by utilizing at least three variants of an immunogenic protein derived from different strains of a pathogenic organism. Another significant patent pertains to HLA binding vaccine moieties, which involve an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules. This invention enhances immune responses after vaccination by effectively targeting antigens to antigen-presenting cells.
Career Highlights
Bjarne Bogen has had a distinguished career, working with esteemed institutions such as the University of Oslo and Vaccibody AS. His expertise in vaccine development has positioned him as a key figure in the field, contributing to advancements that have the potential to improve public health outcomes.
Collaborations
Bogen has collaborated with notable colleagues, including Inger Sandlie and Agnete Brunsvik Fredriksen. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in vaccine research.
Conclusion
Bjarne Bogen's contributions to vaccine technology through his numerous patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in immunology and vaccine development.